Announced Fri, 22 May · 11:30 IST

Receipt of Assessment Order(s) by certain subsidiaries from Income Tax Department

Enforcement RaidRegulatory & Legal View source PDF

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.5%1-day move
₹523.50
prior close
₹520.90
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+0.0+0.1+0.0-0.5+1.7+2.4-0.1+0.3+3.2+18.2+17.5+33.0
Up moveDown movePending
AI summary

Four wholly-owned subsidiaries of Akums Drugs — Maxcure Nutravedics Limited, Pure and Cure Healthcare Private Limited, Malik Lifesciences Private Limited, and Nicholas Healthcare Limited — have received assessment orders from the Income Tax Department (Deputy Commissioner, Central Circle 1, New Delhi) under Section 158BC of the Income Tax Act, 1961, covering the block period 01.04.2018 to 12.03.2025. The combined tax demand across all four subsidiaries totals Rs. 24,68,33,648 (approximately Rs. 24.7 crore), driven by disallowance of various expenditures under Section 37(1) of the Act. The company states it does not expect material financial impact as the demands are defendable, and all four subsidiaries intend to pursue appeals under applicable law.

Likely market impact

The combined demand of ~Rs. 24.7 crore is material but the company has downplayed the impact, signalling confidence in its legal position. While the matter is under appeal and likely to be contested, it introduces regulatory uncertainty and potential cash flow risk for the group.